Precision NanoSystems is a Top 10 Finalist in the 2011 BCIC New Ventures Competition

Press Release

August 29, 2011

Precision NanoSystems has advanced to the final round of top 10 companies in the British Columbia Innovation Council (BCIC) New Ventures Competition.  The New Ventures program is one of North America’s largest emerging technology business plan competitions, with over 175 entrants in 2011 competing over four rounds to win cash prizes.

James Taylor, Ph.D., CEO of Precision NanoSystems said, “This is an exciting accomplishment for Precision.  Precision started operations less than 10 months ago and has gained significant momentum since inception. Being able to compete with some of British Columbia’s most exciting emerging technology businesses this early in our existence speaks highly of the impact for our technology to transform healthcare.”

A total of $375,000 in prizes will be announced at the BCIC-New Ventures Awards on September 22, 2011 in Vancouver.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.

About the BCIC-New Ventures Competition

The BCIC-New Ventures Competition supports BC’s emerging and dynamic technology industry. Established in 2001, the BCIC-New Ventures Competition is operated by the non-profit New Ventures BC Society and made possible through the generous support of BCIC, private and public sponsors, and volunteer mentors, speakers and judges.
www.newventuresbc.com


IN THE NEWS

Press Release

CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology. Precision NanoSystems will lead RNA vaccine formulation development. CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials

Read More



Press Release

Precision NanoSystems, Inc. (PNI), a privately held biotechnology company developing proprietary microfluidic-based manufacturing technology for the use and development of cutting edge nanomedicines, has been invited to speak at the 2013 Internatio...

Read More